Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
Neuroscience ; 235: 149-58, 2013 Apr 03.
Article in English | MEDLINE | ID: mdl-23380501

ABSTRACT

Stress activates the hypothalamus-pituitary-adrenal (HPA) axis leading to the release of glucocorticoids (GC). Increased activity of the HPA axis and GC exposure has been suggested to facilitate the development of obesity and metabolic syndrome. Nonetheless, different stressors can produce distinct effects on food intake and may support different directions of food learning e.g. avoidance or acceptance. This study examined whether interoceptive (LiCl and exendin-4) and restraint stress (RS) support similar or distinct food learning. Female rats were exposed to different stressors after their consumption of a palatable food (butter icing). After four palatable food-stress pairings, distinct intakes of the butter icing were observed in rats treated with different stressors. Rats that received butter icing followed by intraperitoneal injections of LiCl (42.3mg/kg) and exendin-4 (10µg/kg) completely avoided the palatable food with subsequent presentations. In contrast, rats experiencing RS paired with the palatable food increased their consumption of butter icing across trials and did so to a greater degree than rats receiving saline injections. These data indicate that interoceptive and psychosocial stressors support conditioned food avoidance and acceptance, respectively. Examination of c-Fos immunoreactivity revealed distinct neural activation by interoceptive and psychosocial stressors that could provide the neural basis underlying opposite direction of food acceptance learning.


Subject(s)
Avoidance Learning/physiology , Eating/physiology , Eating/psychology , Food Preferences/physiology , Food Preferences/psychology , Stress, Psychological/psychology , Animals , Antimanic Agents/pharmacology , Binge-Eating Disorder/psychology , Body Weight/physiology , Conditioning, Operant/physiology , Data Interpretation, Statistical , Exenatide , Female , Immunohistochemistry , Lithium Chloride/pharmacology , Peptides/pharmacology , Proto-Oncogene Proteins c-fos/metabolism , Rats , Rats, Sprague-Dawley , Restraint, Physical , Venoms/pharmacology
2.
Int J Obes (Lond) ; 37(2): 272-8, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22310470

ABSTRACT

OBJECTIVE: One developing strategy for obesity treatment has been to use combinations of differently acting pharmacotherapies to improve weight loss with fewer adverse effects. The purpose of this study was to determine whether the combination of naltrexone (Nal), an opioid antagonist acting on the reward system, and exendin-4 (Ex-4), a glucagon-like peptide 1 agonist acting on satiety signaling, would produce larger reductions in food intake than either alone in rats. Because the anorectic potencies of both compounds have been associated with nausea and malaise, the influence of these drug combinations on the acquisition of a conditioned taste aversion (CTA) was also determined. METHODS: In Experiment 1, the acute anorectic effects of Nal (0.32-3.2 mg kg(-1); intraperitoneally (i.p.)) and Ex-4 (1-10 µg kg(-1); i.p.) were assessed alone or in combination. Combinational doses were further investigated by the repeated daily administration of 1 mg kg(-1) Nal+3.2 µg kg(-1) Ex-4 for 4 days. In Experiment 2, both compounds alone or in combination were used as unconditioned stimuli in a series of CTA tests. RESULTS: Nal and Ex-4, alone or in combination, suppressed food intake in a dose-dependent manner, and the interaction on food intake between Nal and Ex-4 was additive. In the CTA paradigm, Nal (1 mg kg(-1)) alone did not support acquisition, whereas a CTA was evident with doses of Ex-4 (1 or 3.2 µg kg(-1)). Combinations of Nal and Ex-4 also resulted in a more rapid and robust acquisition of a CTA. CONCLUSION: Given that the Nal and Ex-4 combination produces additive effects on not only food intake reduction but also food aversion learning, this specific drug combination does not have the benefit of minimizing the adverse effects associated with each individual drug. These data suggest that it is necessary to evaluate both the positive and adverse effects at early stages of combinational drug development.


Subject(s)
Appetite Depressants/pharmacology , Eating/drug effects , Hypoglycemic Agents/pharmacology , Naltrexone/pharmacology , Obesity/drug therapy , Peptides/pharmacology , Venoms/pharmacology , Animals , Body Weight/drug effects , Drug Interactions , Drug Therapy, Combination , Exenatide , Male , Obesity/prevention & control , Rats , Rats, Sprague-Dawley , Taste/drug effects , Weight Loss/drug effects
3.
Apoptosis ; 10(6): 1345-56, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16215682

ABSTRACT

The chemical compound ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F), isolated from the Chinese herbal medicine plant Pteris semipinnata L, has been known to exert antitumor activity. However, the molecular mechanism of the action is not understood. In this study we demonstrated that apoptotic cell death induced by 5F in FRO cells was concentration- and time-dependent. The rapid increase in intracellular reactive oxygen species (ROS) levels was involved in the mechanism of cell death. c-Jun N-terminal kinase (JNK) activation and G2 block were related to cell death induced by 5F. Extracellular signal-related kinase (ERK) and p38 were also activated, but as survival signals in response to 5F treatment to counteract the induction of cell death. In the process of the induction of apoptotic cell death, Bax translocated into mitochondria, a reduction in Delta psi(m) was observed and a release of cytochrome c and apoptosis inducing factor (AIF) from mitochondria into the cytosol occurred, indicating that cell death induced by 5F was through a mitochondrial-mediated pathway.


Subject(s)
Carcinoma/pathology , Diterpenes/pharmacology , Drugs, Chinese Herbal/pharmacology , Thyroid Neoplasms/pathology , Apoptosis Inducing Factor/metabolism , Carcinoma/enzymology , Caspase 3/metabolism , Cell Death/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Cytochromes c/metabolism , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , G2 Phase/drug effects , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Membrane Potential, Mitochondrial/drug effects , Mitochondria , Poly(ADP-ribose) Polymerases/metabolism , Protein Transport/drug effects , Reactive Oxygen Species/metabolism , Thyroid Neoplasms/enzymology , Time Factors , p38 Mitogen-Activated Protein Kinases/metabolism
4.
Apoptosis ; 9(5): 619-27, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15314290

ABSTRACT

Ent-11 alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F), an antitumor component, is a chemical compound isolated from Pteris semipinnata L (PsL), a Chinese traditional herb. We examined whether 5F could affect apoptosis in human colon cancer HT-29 cells, and test whether and how the over-expression of Bcl-2 and Bcl-xL could offset the effect of 5F on cell growth. The result demonstrated that 5F significantly induced apoptosis of HT-29, as shown by MTT assay and DNA fragmentation measurement. Treatment of HT-29 with 5F increased both p38 and iNOS levels, suggesting these two molecules may contribute to the apoptotic effect of 5F. Over-expression of Bcl-2 or Bcl-xL attenuated the increase of p38 and iNOS induced by 5F. The cells with Bcl-2 or Bcl-xL over-expression showed an elevation of nuclear factor kappa B (NF-kappa B) activity, accompanying a significant reduction of 5F-induced apoptosis. Furthermore, inhibition of NF-kappa B by I k B alpha SR, which is a powerful inhibitor of NF-kappa B, restored the ability of 5F to induce apoptosis in the cells transfected with Bcl-2. These data strongly indicated that the apoptotic effect of 5F on HT-29 was closely associated with the activity of NF-kappa B, which was up-regulated by Bcl-2 and Bcl-xL. In conclusion, 5F induced apoptosis in HT-29 cells and this apoptotic effect was associated with the high level of p38 and iNOS expression. The apoptotic effect of 5F could be significantly offset by over-expression of either Bcl-2 or Bcl-xL. Bcl-2, and to the less extent, Bcl-xL, were able to increase the activity of NF-kappa B, which was a known anti-apoptotic molecule in human colon cancer cells.


Subject(s)
Apoptosis/physiology , Diterpenes/toxicity , Medicine, Chinese Traditional , NF-kappa B/physiology , Proto-Oncogene Proteins c-bcl-2/genetics , Pteris , Cell Death/drug effects , Cell Line, Tumor , Colonic Neoplasms , DNA Fragmentation , Humans , Phytotherapy , Proto-Oncogene Proteins c-bcl-2/metabolism , bcl-X Protein
5.
Acta Pharmacol Sin ; 22(5): 428-34, 2001 May.
Article in English | MEDLINE | ID: mdl-11743891

ABSTRACT

AIM: To determine the effect of ginsenosides (GSL) on ovariectomized rats by analysis of cancellous bone histomorphometry. METHODS: Forty Sprague-Dawley female rats at age of 3 months were sham-operated (Sham, n = 8) and treated orally with vehicle, or ovariectomized (OVX, n = 32 which were divided into three group with n = 8 per group) and treated orally with either vehicle, 17alpha-ethynylestradiol (EE, 100 microg . kg-1 . d-1), or ginsenosides (GSL) at 100 or 300 mg . kg-1 . d-1 for 10 weeks. Double in vivo fluorochrome labeling was administrated. The undecalcified longitudinal proximal tibial metaphyseal sections were cut and stained with Goldner's Trichrome (4-micron thickness) or unstained (8-micron thickness) for the bone histomorphometric analysis. RESULTS: After 10 weeks post OVX the cancellous bone mass was lost markedly and showed high bone turnover indices (increased bone resorption and formation). EE decreased the resorptive surface and bone formation rate related to bone turnover and prevented bone loss. GSL at the two doses (100 and 300 mg . kg-1 . d-1) reduced the resorptive surfaces as did EE, but did not depress the mineral bone formation. High dose of GSL greatly increased bone mass and had a tendency to decrease bone turnover when compared with OVX group. CONCLUSION: GSL partially prevented OVX-induced cancellous bone loss by inhibiting osteoclast bone resorption and by a mild depression of bone turnover.


Subject(s)
Bone Diseases, Metabolic/prevention & control , Ginsenosides/therapeutic use , Tibia/pathology , Animals , Bone Diseases, Metabolic/etiology , Ethinyl Estradiol/pharmacology , Female , Osteoclasts/drug effects , Osteogenesis/drug effects , Ovariectomy/adverse effects , Rats , Rats, Sprague-Dawley
6.
Acta Pharmacol Sin ; 21(5): 445-9, 2000 May.
Article in English | MEDLINE | ID: mdl-11324444

ABSTRACT

AIM: To study the effect of 5-(N,N-dimethyl) amiloride (DMA) on the proliferation and differentiation of HL-60 cells in vitro. METHODS: MTT assay to test cytotoxicity; cell staining and NBT reduction to test cell differentiation. RESULTS: DMA inhibited HL-60 cells growth in a concentration-dependent manner, and IC50 value for 96 h was 31.7 (95% confidence limits: 6.3-57.1) mumol.L-1. DMA also induced granulocytic differentiation in HL-60 cells. The percentage of differentiating cells increased from 6.5% to 70% after DMA 100 mumol.L-1 treatment for 3 d. The differentiating effect of DMA was distinguishable from amiloride, 5-(N-ethyl-N-isopropyl)amiloride (EIPA), and (5-(N-ethyl-N-isopropyl)amiloride (MIA). None among the amiloride, EIPA, and MIA were capable of triggering the differentiation of HL-60 cells. CONCLUSION: DMA inhibited the proliferation of HL-60 cells and induced differentiation of HL-60 cells.


Subject(s)
Amiloride/pharmacology , Cell Transformation, Neoplastic/drug effects , Amiloride/analogs & derivatives , Cell Division/drug effects , HL-60 Cells/drug effects , Humans , Inhibitory Concentration 50
7.
Acta Pharmacol Sin ; 21(8): 737-41, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11501184

ABSTRACT

AIM: To study the inhibitory effect of semi-synthesized quercetin derivatives--disodium quercetin-7,4'-disulfate (DQD) on the platelet aggregation induced by thrombin and its mechanism. METHODS: Platelet aggregation was analysed by turbidimetry. Cytosolic free calcium concentration ([Ca2+]i) was determined by Fura-2 fluorescence technique. Activity of Ca2+/PL dependent protein kinase C (PKC) was assayed by incubating PKC with histone III S and [gamma-32P]ATP. The cytoskeletal proteins were precipitated by Triton and separated by SDS-PAGE. RESULTS: DQD inhibited the platelet aggregation induced by thrombin (500 U/L), when DQD concentrations were 100, 200, and 400 mumol/L, the inhibition rates were 77%, 86%, and 82% respectively. DQD inhibited Ca2+ influx in platelets induced by thrombin (500 U/L) in the presence of extracellular Ca2+ 1 mmol/L in a concentration-dependent manner (10-80 mumol/L); DQD also had inhibitory effect on intracellular Ca2+ mobilization in the absence of extracellular Ca2+. DQD (10-160 mumol/L) inhibited the cytosolic Ca2+/PL dependent PKC from platelets in a concentration-dependent manner, but had no effect on membrane PKC. DQD (20-200 mumol/L) inhibited the actin polymerization induced by thrombin (500 U/L) in platelets in a concentration-dependent manner. CONCLUSION: DQD inhibited pig platelet aggregation induced by thrombin and its molecular mechanism was due to its inhibition of Ca2+ influx, intracellular Ca2+ mobilization, Ca2+/PL dependent PKC activity, and actin polymerization.


Subject(s)
Calcium/blood , Fibrinolytic Agents/pharmacology , Platelet Aggregation/drug effects , Quercetin/pharmacology , Actins/blood , Animals , Biological Transport, Active , Blood Platelets/metabolism , Protein Kinase C/blood , Quercetin/analogs & derivatives , Swine
8.
J Bone Miner Metab ; 17(1): 18-22, 1999.
Article in English | MEDLINE | ID: mdl-10084397

ABSTRACT

To study the skeletal effects of continual and terminated use of risedronate treatment on cortical bone in ovariectomized (Ovx) rats, we used risedronate (Ris), 5 microg x kg(-1), by subcutaneous injections, twice per week. The middle part of the tibial shafts (Tx) were processed undecalcified for quantitive bone histomorphometry. Cortical bone and the marrow areas of the tibial shaft did not change in either sham-Ovx or Ovx rats during the 150-day experimental period. Continued administration of Ris for 150 days decreased the marrow area and increased the percentage of cortical area compared with the matching sham and Ovx group. A decrease in bone formation indices in both periosteal and endocortical surfaces of Tx in sham-operated rats between the age of 5 and 8 months was seen. Ovariectomy increased the percentage of labeled perimeter in the periosteal area, and markedly increased the percentage of eroded perimeter in the endocortical surface compared with sham control groups in 81 and 150 days. Bone formation indices of Ris treatment were increased in periosteal surfaces, and percentages of eroded perimeter were decreased more in endocortical surfaces in 150 days than in the matching sham and Ovx groups. These data matched our static data, which showed a significantly increased percentage of cortical bone area and decreased percentage of marrow area. These bone gains were not maintained in the 90-day Ris withdrawal group. For cancellous bone, the 60-day Ris-treated high bone mass was maintained in the withdrawal group and not maintained in Ris continmuously treated group. These results indicate the effects of constant and terminated use of Ris in cortical bone were different from those in trabecular bone in the proximal tibial metaphysis.


Subject(s)
Bone and Bones/drug effects , Bone and Bones/pathology , Etidronic Acid/analogs & derivatives , Animals , Bone Remodeling/drug effects , Disease Models, Animal , Drug Administration Schedule , Etidronic Acid/administration & dosage , Etidronic Acid/pharmacology , Female , Osteoporosis/drug therapy , Osteoporosis/etiology , Osteoporosis/pathology , Ovariectomy/adverse effects , Rats , Rats, Sprague-Dawley , Risedronic Acid , Tibia/drug effects , Tibia/pathology , Time Factors
9.
Zhongguo Yao Li Xue Bao ; 20(7): 623-6, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10678126

ABSTRACT

AIM: To study the inhibitory effects of sodium quercetin monosulfate (SQMS) on pig platelet aggregation induced by thrombin. METHODS: Platelet aggregation was analyzed by turbidimetry. Cytosolic free calcium concentration ([Ca2+]i) was determined by Fura-2 fluorescence. Activity of protein kinase C (PKC) was assayed by incubating PKC with histone III S and [gamma-32 P] ATP. The cytoskeletal proteins were precipitated by Triton X-100 and separated by SDS-PAGE. RESULTS: SQMS inhibited the platelet aggregation induced by thrombin 500 U.L-1 with IC50 132 (50-347) mumol.L-1. SQMS inhibited Ca2+ influx in blood platelets induced by thrombin 500 U.L-1 in the presence of extracellular Ca2+ 1 mmol.L-1 with IC50 20 (9-46) mumol.L-1; SQMS inhibited the internal Ca2+ release in the absence of extracellular Ca2+. SQMS also decreased [Ca2+]i level in quiescent blood platelets. SQMS (10-160 mumol.L-1) inhibited the activity of cytosolic PKC from blood platelets in a concentration-dependent manner, but had no effect on membrane PKC. SQMS (20-80 mumol.L-1) inhibited the actin polymerization induced by thrombin 500 U.L-1 inblood platelets in a concentration-dependent manner. CONCLUSION: SQMS inhibited pig platelet aggregation induced by thrombin and its mechanism might be due to its inhibitions of Ca2+ influx, internal Ca2- release, PKC activity, and actin polymerization.


Subject(s)
Calcium/blood , Platelet Aggregation Inhibitors/pharmacology , Quercetin/pharmacology , Actins/metabolism , Animals , Protein Kinase C/blood , Quercetin/analogs & derivatives , Swine , Thrombin/pharmacology
10.
Zhongguo Yao Li Xue Bao ; 20(6): 541-5, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10678150

ABSTRACT

AIM: To study the effect of the antitumor compounds 5F, 6F, and A from Pteris semipinnata L on the activities of DNA topoisomerases and cell cycle of HL-60 cells, and the synergism of compound 6F in combination with genistein in vitro. METHODS: DNA topoisomerases were isolated from HL-60 cell lines, and supercoiled pBR322 DNA was used as substrate to determine the activities of DNA topoisomerase I and II. Cell cycle was analyzed by flow cytometry (FCM). Cytotoxicity assay was tested by MTT method. RESULTS: Compounds 5F, 6F, and A inhibited the activities of DNA topoisomerase I and II. After exposure of the cells to compound 6F, an increase in cells in the S and G2/M phases and a decrease in cells in the G0/G1 phase of the cell cycle were observed. At low concentrations (57.8 and 115.6 nmol.L-1), compound 6F enhanced the cytotoxicity against HL-60 cell line in combination with genistein, q values were > 1.15. The enhancement times of 57.8 and 115.6 nmol.L-1 of 6F by genistein were 2.60 and 4.65, respectively. CONCLUSION: Compounds 5F, 6F, and A inhibited the activities of DNA topoisomerases of HL-60 cells. Compound 6F increased the number of cells in S and G2/M phases, decreased the population of G0/G1 phase cells, and enhanced the cytotoxicity of genistein, which had synergism with 6F in antitumor action.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , DNA Topoisomerases, Type II/metabolism , DNA Topoisomerases, Type I/metabolism , Drugs, Chinese Herbal/pharmacology , Cell Cycle , Drug Synergism , Genistein/pharmacology , HL-60 Cells/enzymology , HL-60 Cells/pathology , Humans
11.
Zhongguo Yao Li Xue Bao ; 19(2): 160-3, 1998 Mar.
Article in English | MEDLINE | ID: mdl-10374643

ABSTRACT

AIM: To study the skeletal effects of constant and terminated use of sodium risedronate (Ris) treatment in the ovariectomized (Ova) rats. METHODS: Ris 5 micrograms.kg-1, s.c., twice a wk. The proximal tibial metaphysis (PTM) were processed undecalcified for quantitive bone histomorphometry. RESULTS: (1) Placebo-treated (normal saline) Ova rats were characterized by decreased trabecular area (TA) on d 60, d 81, and d 150 compared with aging controls, and bone resorption was over formation with high bone turnover. (2) Ova rats were treated with Ris for 60, 81, and 150 d (Ris-on) increased. (TA 217%, 108%, and 101%) respectively, vs Ova rats and depressed bone turnover indices to aging control level, but bone mass did not maintain at high level in 150-d group as in the early stage. (3) Ova rats were pretreated with Ris for 60 d and then terminated (Ris-on/off), followed by sequential sacrifice of rats on 21 and 90 d. Withdrawal on 21 d showed the same results as the match-age Ris-on group. Withdrawal on 90 d still maintained cancellous bone mass at a high level vs 150 d Ris-on groups (+26%) and aging control group (+27%). CONCLUSION: Regimen of Ris 60 d on then 90 d off prevented the development of osteoporosis in Ova rats.


Subject(s)
Calcium Channel Blockers/therapeutic use , Etidronic Acid/analogs & derivatives , Osteoporosis, Postmenopausal/prevention & control , Animals , Bone Resorption/prevention & control , Calcium Channel Blockers/administration & dosage , Etidronic Acid/administration & dosage , Etidronic Acid/therapeutic use , Female , Humans , Ovariectomy , Rats , Rats, Sprague-Dawley , Risedronic Acid , Tibia
12.
Zhongguo Yao Li Xue Bao ; 19(6): 540-2, 1998 Nov.
Article in English | MEDLINE | ID: mdl-10437141

ABSTRACT

AIM: To study the effects of genistein on aggregation and cytosolic free calcium concentration in platelets. METHODS: Using turbidimetry to analyse aggregation and using Fura-2 fluorescence technique to determine Ca2+ level. RESULTS: Genistein strongly inhibited the pig platelet aggregation induced by thrombin (250 U.L-1). When genistein concentrations were 5 and 20 mumol.L-1, the inhibition rates on the aggregation were 52% and 73%, respectively. Genistein inhibited the rise of cytosolic free calcium concentration in platelets stimulated by thrombin (500 U.L-1) in the presence of extracellular Ca2+ 1 mmol.L-1. When genistein concentrations were 10, 20, 40, and 80 mumol.L-1, the inhibition rates were 24%, 40%, 63%, and 65%, respectively, but no effect on thrombin-induced internal Ca2+ release from dense tubular system. CONCLUSION: Genistein is a potential anti-platelet agent, mainly due to an inhibition of Ca2+ influx.


Subject(s)
Calcium/blood , Genistein/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation/drug effects , Animals , Biological Transport, Active , Blood Platelets/metabolism , Swine
13.
Biochem Pharmacol ; 54(9): 1013-8, 1997 Nov 01.
Article in English | MEDLINE | ID: mdl-9374422

ABSTRACT

Quercetin, a naturally occurring flavonoid, has been shown to exert multiple pharmacological effects and to be an anticancer agent or a supplementary anticancer agent. In this report, the human HL-60 promyelocytic leukemia cell line was used to study the effects of quercetin on the growth, cell cycle, activities of cytosolic and membrane protein kinase C (PKC) and tyrosine protein kinase (TPK), and phosphoinositide production of the tumor cells. The results showed that quercetin inhibited the growth of HL-60 cells in a concentration-dependent manner, with an IC50 value of about 7.7 microM after 96 hr of treatment; when the concentration of quercetin was 10 microM, the percent inhibition on the growth of HL-60 cells was 17.1, 27.3, 40.1, and 52.7% after 24, 48, 72, and 96 hr of treatment, respectively. Flow cytometric analyses showed that quercetin caused an increase in cells in the G2/M phase and a decrease in cells in the G0/G1 phase of the cell cycle in a concentration-dependent manner; these effects were reversed when quercetin was removed from the culture medium. Quercetin strongly inhibited the activities of cytosolic PKC and membrane TPK from HL-60 cells in vitro, with IC50 values of about 30.9 and 20.1 microM, respectively, but did not affect membrane PKC or cytosolic TPK activity from HL-60 cells in vitro. Quercetin markedly inhibited in a concentration-dependent manner the production of phosphoinositides in intact HL-60 cells. The results provide evidence that the inhibitory effect of quercetin on the growth of HL-60 cells may be related to its inhibitory effects on PKC and/or TPK in vitro and/or on the production of phosphoinositides.


Subject(s)
Antineoplastic Agents/pharmacology , Quercetin/pharmacology , Cell Cycle/drug effects , Cell Division/drug effects , HL-60 Cells , Humans , Phosphatidylinositols/metabolism , Protein Kinase C/metabolism , Protein-Tyrosine Kinases/metabolism
14.
Zhongguo Yao Li Xue Bao ; 18(4): 374-6, 1997 Jul.
Article in English | MEDLINE | ID: mdl-10072927

ABSTRACT

AIM: To study the effect of quercetin (Que) on the activities of cytosol and membrane protein kinase C (PKC) and tyrosine protein kinase (TPK) from HL-60 cells in vitro. METHODS: The number of viable cells was counted by a trypan blue dye exclusion test. PKC activity was assayed by incubating PKC with histone III S and [gamma-32P]ATP. TPK activity was assayed by incubating TPK with poly glutamate.tyrosine (4:1). RESULTS: Que inhibited the proliferation of HL-60 cells in a concentration-dependent manner, its IC50 was 29 (22-37) mumol.L-1 after 48-h treatment; Que strongly inhibited the activity of cytosol PKC and membrane TPK with IC50 31 (20-48) mumol.L-1, 24 (13-45) mumol.L-1, respectively, but did not affect membrane PKC and cytosol TPK from HL-60 cells in vitro. CONCLUSION: The inhibitory effect of Que on the growth of tumor cells is related to its inhibitory effects on PKC and/or TPK.


Subject(s)
Enzyme Inhibitors/pharmacology , Protein Kinase C/metabolism , Protein-Tyrosine Kinases/metabolism , Quercetin/pharmacology , Cell Division/drug effects , Cell Membrane/enzymology , Cytosol/enzymology , HL-60 Cells/enzymology , Humans
15.
Zhongguo Yao Li Xue Bao ; 18(3): 286-8, 1997 May.
Article in Chinese | MEDLINE | ID: mdl-10072954

ABSTRACT

AIM: To compare the total coumarins from dried fruits of Cnidium monnieri (TCCM) and nilestriol (Nil) against osteoporosis. METHODS: SD rats (40, female, 3-month-old) were randomly divided into basal control, age control, ovariectomized (Ova), Ova + TCCM 67 mg.kg-1, Ova + TCCM 200 mg.kg-1, 6 times a week, and Ova + Nil 1 mg.kg-1, i.g. once a week. After 12 wk, sections (20 microns) of proximal tibiae were examined histologically. RESULTS: Ova reduced markedly the trabecular bone mass due to bone resorption excessed bone formation (% Tb. Ar -59%). Treatment with TCCM 67 mg.kg-1 partly suppressed bone turnover, but did not inhibit bone loss in Ova rats (% Tb.Ar -43%). Treatment with TCCM 200 mg.kg-1 and Nil 1 mg.kg-1 increased the trabecular area (% Tb. Ar +100% and +274%). CONCLUSION: Nil was more potent than TCCM in protecting against osteoporosis in Ova rats via supression of bone turnover.


Subject(s)
Apiaceae , Coumarins/therapeutic use , Osteoporosis, Postmenopausal/prevention & control , Quinestrol/analogs & derivatives , Animals , Apiaceae/chemistry , Bone Resorption/prevention & control , Coumarins/isolation & purification , Female , Humans , Ovariectomy , Quinestrol/therapeutic use , Random Allocation , Rats , Rats, Sprague-Dawley , Tibia
16.
Zhongguo Yao Li Xue Bao ; 18(1): 56-8, 1997 Jan.
Article in English | MEDLINE | ID: mdl-10072895

ABSTRACT

AIM: To study the action of tyrphostin on casein kinase (CK) II. METHODS: CK II was partially purified from rat livers by sequential DE52 and heparin-Sepharose chromatography. CK II activity was assayed by incubating CK II with dephosphorylated casein and [gamma-32P]ATP. RESULTS: AG34 inhibited the activity of CK II with IC50 33 (27-41) mumol.L-1. Both AG372 (121 mumol.L-1) and AG1112 (150 mumol.L-1) displayed inhibitory effects on the activity of CK II. Kinetic studies of AG34 on CK II showed that it was noncompetitive with casein and ATP. CONCLUSION: AG34, AG372, and AG1112 were potent inhibitors of CK II, and the inhibitory action of AG34 was noncompetitive with casein and ATP.


Subject(s)
Liver/enzymology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Animals , Casein Kinase II , Catechols/pharmacology , DNA-Binding Proteins/metabolism , Female , Protein Serine-Threonine Kinases/metabolism , Rats , Rats, Sprague-Dawley , Tyrphostins/pharmacology
17.
Zhongguo Yao Li Xue Bao ; 17(4): 353-6, 1996 Jul.
Article in English | MEDLINE | ID: mdl-9812723

ABSTRACT

AIM: To investigate the effects of tyrphostins, (AG213, AG1394, AG114, AG1109, AG555) on the activity of casein kinase (CK) II. METHODS: CK II was partially purified from rat livers by sequential DE52 and heparin-Sepharose chromatography. CK II activity was assayed by incubating CK II with dephosphorylated casein and [gamma-32 P]ATP. RESULTS: AG213 inhibited the activity of CK II with IC50 44.7 mumol.L-1 (41.5-47.9 mumol.L-1), and AG1394 (144 mumol.L-1) strongly inhibited the activity of CK II with an inhibitory ratio of 89%. AG114 (174 mumol.L-1) and AG1109 (126 mumol.L-1) had inhibitory effects on the activity of CK II (p < 0.01). AG555 (136 mumol.L-1) had little effect on CK II activity. CONCLUSION: Some tyrphostins are potent inhibitors of CK II.


Subject(s)
Enzyme Inhibitors/pharmacology , Liver/enzymology , Protein Serine-Threonine Kinases/metabolism , Tyrphostins/pharmacology , Animals , Casein Kinase II , Liver/chemistry , Protein Serine-Threonine Kinases/isolation & purification , Rats
18.
Yao Xue Xue Bao ; 31(5): 327-32, 1996.
Article in Chinese | MEDLINE | ID: mdl-9275709

ABSTRACT

Thirty-one 3-month-old Female Sprague-Dawley rats were randomly divided into 5 groups, basal control (group 1, killed at the begining), aging control (group 2), ovariectomized (OVX, group 3), OVX with nilestriol treatment group (group 4) and OVX with osthole treatment group (group 5). Group 2 and group 3 ig with water 5 ml.kg-1 and group 5 ig with osthole 6.7 mg.kg-1, all once a day for 6 d; group 4 ig with nilestriol 1 mg.kg-1, once a week. After 12 weeks, all rats were killed. The proximal tibiae of rats were processed to undecalcified sections at 20 microns thickness for histomorphometric analysis. OVX was shown to reduce markedly the trabecular bone mass (%Tb. Ar-59%) due to increase of bone turnover with the result that bone resorption exceeded bone formation, as compared with aging controls. In contrast, treatment of OVX rats with Osthole and nilestriol increased significantly the trabecular area (increased 68% and 27.1% compared with that of OVX respectively). Our results indicate that osthole and nilestriol treatment provides protection against osteoporosis in OVX rats. The protective mechanism of osthole and nilestriol involves supression of bone turnover, but the effects of osthole is lower than that of nilestriol (trabecular area decreased 55% more in osthole group than that with nilestriol treatment). Our finding may provide theoretical evidence for the clinical use of osthole or nilestriol for treatment and prevention of osteoporosis.


Subject(s)
Calcium Channel Blockers/therapeutic use , Coumarins/therapeutic use , Osteoporosis, Postmenopausal/prevention & control , Quinestrol/analogs & derivatives , Animals , Bone Resorption/prevention & control , Delayed-Action Preparations , Female , Humans , Ovariectomy , Quinestrol/therapeutic use , Random Allocation , Rats , Rats, Sprague-Dawley , Tibia/metabolism
19.
Bone ; 17(4 Suppl): 261S-266S, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8579926

ABSTRACT

Pretreatment of an anti-resorptive agent on the anabolic effects of prostaglandin E2 (PGE2) was studied on the proximal tibia and tibial shaft of ovariectomy (ovx) rats. Two days after ovx, rats were treated with either risedronate (Ris, 5 micrograms/kg twice weekly) or vehicle (V) for 60 days and then switched to 3 or 6 mg/kg/d PGE2 for 21 or 90 days. Bone area of both proximal tibial metaphysis (PTM) and tibial shaft (TX) were measured. Pretreatment with Ris increased the bone mass in PTM but not in TX of ovx rats. In the PTM, PGE2 produced the same percentage of new bone mass in both V- and Ris-pretreated ovx rats. The amount of new bone was almost the same after 3 weeks and 12 weeks of PGE2 treatment. There was no difference in the anabolic effects of 3 and 6 mg PGE2/kg/d in V-pretreated rats; however, the effects in Ris-pretreated groups were greater with 6 mg PGE2/kg/d than with 3 mg PGE2/kg/d. In TX, only the 6mg PGE2/kg/d administration added new bone on endocortical surfaces of both V- or Ris-pretreatment rats which leads to thickening the minimal cortical width, decreasing the marrow cavity and increasing total bone area. Both doses of PGE2 created new trabecular bone in the marrow cavity of tibial shaft in both vehicle- and Ris-pretreated ovx rats. These results suggest that Ris-pretreatment did not hamper the anabolic effects of PGE2 on either PTM or TX in ovx rats.


Subject(s)
Dinoprostone/pharmacology , Etidronic Acid/analogs & derivatives , Ovary/physiology , Tibia/drug effects , Aging/metabolism , Animals , Drug Evaluation, Preclinical , Drug Interactions , Etidronic Acid/pharmacology , Female , Ovariectomy , Rats , Rats, Sprague-Dawley , Reference Values , Risedronic Acid , Tibia/metabolism
20.
Zhongguo Yao Li Xue Bao ; 16(3): 247-50, 1995 May.
Article in English | MEDLINE | ID: mdl-7660821

ABSTRACT

AIM: To study the effects of adenosine on the phosphorylation of phosphoinositides and proteins in platelets. METHODS: In the presence of Mg2+ and/or Ca2+, swine thrombocytic membranes were incubated with [gamma-32P]ATP at 30 degrees C for 3 min and the incorporations of 32P into phospholipids or proteins were measured. RESULTS: 5'-Chloro-5'-deoxyadenosine decreased the formation of phosphatidylinositol 4-phosphate and phosphatidylinositol 4, 5-bisphosphate [IC50 71 and 75 (95% confidence limits 60-85 and 62-90) mumol.L-1, respectively], behaving as a competitive inhibitor to ATP, and inhibited the phosphorylation of pleckstrin (the major protein kinase C substrate) and myosin light chain [IC50 75 and 82 (95% confidence limits 62-90 and 66-102) mumol.L-1, respectively]. CONCLUSION: Adenosine affects the phosphoinositide signaling pathway in platelets, which helps to clarify the inhibition of adenosine on platelet activation.


Subject(s)
Blood Platelets/metabolism , Blood Proteins/metabolism , Cladribine/pharmacology , Myosin Light Chains , Phosphatidylinositol Phosphates/biosynthesis , Phosphoproteins , Animals , Myosins/metabolism , Phosphatidylinositol 4,5-Diphosphate , Phosphorylation/drug effects , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...